Kringle Pharma, Inc. (JP:4884)
:4884
4884 Stock Chart & Stats
¥379.00
-¥48.00(-4.72%)
At close: 4:00 PM EST
¥379.00
-¥48.00(-4.72%)
Day’s Range― - ―
52-Week Range¥365.00 - ¥1,125.00
Previous CloseN/A
Volume217.60K
Average Volume (3M)51.60K
Market Cap
¥4.13B
Enterprise Value¥2.20B
Total Cash (Recent Filing)¥1.62B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.75
Next Earnings
May 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-28.20
Shares Outstanding8,078,200
10 Day Avg. Volume53,170
30 Day Avg. Volume51,600
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)2.41
Price to Sales (P/S)43.77
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary HGF PlatformKringle’s proprietary Hepatocyte Growth Factor (HGF) platform supports multiple therapeutic programs (spinal cord injury, ALS, inflammatory conditions). A platform approach spreads development risk, enables pipeline scalability, and increases attractiveness for long-term licensing or collaborations.
Low Leverage / No Reported DebtNo reported debt materially lowers solvency risk for a cash-burning biotech, preserving flexibility to pursue R&D or partner deals. This capital structure reduces fixed obligations, improving resilience across funding cycles and extending operational runway relative to indebted peers.
Established Non-dilutive Revenue ChannelsExisting grant, partnership and licensing revenue streams demonstrate an ability to monetize science without sole reliance on product sales. Non-dilutive grants and milestone payments provide durable funding levers, validate technology via external partners, and support longer-term development programs.
Bears Say
Persistent Operating LossesSustained operating and net losses indicate the company has not achieved profitable operations, constraining internal funding for trials and commercialization. Over time, persistent losses raise dilution risk, limit investment in pipeline depth, and pressure shareholder value if clinical milestones lag.
Weak Cash GenerationMaterial negative operating cash flows across multiple years show limited self-funding capacity. Continued cash burn necessitates frequent external financing or partner deals, which can dilute shareholders, delay programs if funding tightens, and increase execution risk for long-term projects.
Declining, Volatile Revenue TrendA falling and inconsistent top line undermines proof of sustainable commercialization or recurring partner income. Chronic revenue decline reduces credibility with collaborators and investors, heightens dependency on one-off funding, and weakens prospects for achieving self-sustaining operations over the medium term.
Kringle Pharma, Inc. News
4884 FAQ
What was Kringle Pharma, Inc.’s price range in the past 12 months?
Kringle Pharma, Inc. lowest stock price was ¥365.00 and its highest was ¥1125.00 in the past 12 months.
What is Kringle Pharma, Inc.’s market cap?
Kringle Pharma, Inc.’s market cap is ¥4.13B.
When is Kringle Pharma, Inc.’s upcoming earnings report date?
Kringle Pharma, Inc.’s upcoming earnings report date is May 11, 2026 which is in 34 days.
How were Kringle Pharma, Inc.’s earnings last quarter?
Kringle Pharma, Inc. released its earnings results on Feb 09, 2026. The company reported -¥28.2 earnings per share for the quarter, missing the consensus estimate of N/A by -¥28.2.
Is Kringle Pharma, Inc. overvalued?
According to Wall Street analysts Kringle Pharma, Inc.’s price is currently Overvalued.
Does Kringle Pharma, Inc. pay dividends?
Kringle Pharma, Inc. does not currently pay dividends.
What is Kringle Pharma, Inc.’s EPS estimate?
Kringle Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kringle Pharma, Inc. have?
Kringle Pharma, Inc. has 8,078,200 shares outstanding.
What happened to Kringle Pharma, Inc.’s price movement after its last earnings report?
Kringle Pharma, Inc. reported an EPS of -¥28.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.806%.
Which hedge fund is a major shareholder of Kringle Pharma, Inc.?
Currently, no hedge funds are holding shares in JP:4884
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kringle Pharma, Inc.
Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.
Technical Analysis
Peptidream
―
NanoCarrier Co., Ltd.
―
Ribomic, Inc.
―
Delta-Fly Pharma, Inc.
―
FunPep Company Limited
―